1 / 15

Diabetes Mellitus 101 for Medical Professionals

Diabetes Mellitus 101 for Medical Professionals. An Aggressive Pathophysiologic Approach to Cardiometabolic Therapy for Type 2 Diabetes :. Part 5. Stan Schwartz MD,FACP Clinical Associate Professor of Medicine, U of Pa. Cardiometabolic Institute Penn-Presbyterian Hospital,, UPHS.

scalvin
Download Presentation

Diabetes Mellitus 101 for Medical Professionals

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Diabetes Mellitus 101 for Medical Professionals An Aggressive Pathophysiologic Approach to Cardiometabolic Therapy for Type 2 Diabetes: Part 5 Stan Schwartz MD,FACP Clinical Associate Professor of Medicine, U of Pa. Cardiometabolic Institute Penn-Presbyterian Hospital,, UPHS

  2. Potential Mechanisms of reducing CV outcomes with DPP-4 inhibitors Fadini,G, Cardiovascular effects off DPP-4 Inhibition, Vascular Pharm., in press, 2011

  3. Exentide and CV outcomes- 430,000 patients-near 40,000 on exenatide Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily orOther Glucose-Lowering Therapies A retrospective analysis of the LifeLink database JENNIE H. BEST, PHD, Diabetes Care 34:90–95, 2011 1

  4. S e c t i o n 12, 12.2 Mechanism of Incretins Incretin Mimetic Glucose dependent Insulin (GLP-1andGIP) Glucose uptake by peripheral tissue Ingestion of food Pancreas Release of active incretins GLP-1 and GIP Beta cells Alpha cells GI tract  Blood glucose in fasting and postprandial states Glucose- dependent X DPP-4 inhibitor DPP-4 enzyme Hepatic glucose production Glucagon (GLP-1) Inactive GLP-1 Inactive GIP • Incretin hormones GLP-1 and GIP are released by the intestine throughout the day, and their levels  in response to a meal. • Incretin Mimetics are resistant to DPP-4 inactivation Concentrations of the active intact hormones are increased by DPP-4 inhibition, thereby increasing and prolonging the actions of these hormones. GLP-1=glucagon-like peptide-1; GIP=glucose-dependent insulinotropic polypeptide.

  5. ? Pancreatitis, ? C-cell tumors ? pancreatitis

  6. Relative differences-sitagliptinvsexenatide

  7. Acutely Improving Beta-Cell ResponseBYETTA Reduced Hyperglycemia in Fasting Patients exenatide exenatide NO HYPO- can use NPO

  8. exenatide WEEK WEIGHT Dec.- Not correlated to nausea 8

  9. Changes in Glycemia and Weight in3 Studies of Exenatide vs Insulin Heine et al1 Nauck et al3 Barnettet al2 Heine et al1 Barnettet al2 Nauck et al3 10 9 Change inA1C, % 8 ADA GOAL 7 -0.9% -1.0% -1.4% -1.1% -1.4% -1.1% 6 Glargine, Once Daily Insulin Aspart, 70/30 Exenatide 4 3 2 1 Change in Weight, kg 0 +2.9 kg +1.8 kg +2.3 kg -1 -2 -2.2 lb -2.3 kg -3 -2.5 kg 1. Heine R, et al. Ann Intern Med. 2005;143:559-569. 2. Barnett AH, et al. Clin Ther. 2007;29:2333-2348. 3. Nauck MA, et al. Diabetologia. 2007;50:259-267.

  10. Easy to Initiate:31- g tips don’t hurt!!All MDs should poke themselves!!! • After first use, BYETTA can be kept at a room temperature not to exceed 77ºF (25ºC) • Initiate with 5-mcg BID fixed dose, prefilled pens • increase dose to 10 mcg BID, based on glycemic / weight response and tolerability • Take BYETTA with first bite , (and only 1 hour before a meal when tolerates 10 Pen) No dosage adjustments based on meal size or exercise • No additional glucose monitoring required

  11. Insulin Secretagogues: Sulfonylureas and “Glinides” • Safety and Efficacy -Decreases HbA1c approx1–2%(sfu, repaglinide)(0.5-1.0%,neteglanide) -Adverse events: Wt gain, sulfa allergy (sfu,rare), -cell apoptosis (sfu) Main risk = hypoglycemia , inc ischemia risk(~50% less w/repaglinide,75% less with neteglanide) Increase Cancer vs Metformin Abnormal ischemia pre-conditioning SO WHY USE SOMETHING THAT DESTROYS BETA-CELLS THAT YOU’D LIKE TO SAVE Davies MJ. Curr Med Res Opin. 2002;18(Suppl 1):s22-30.

  12. Meta-Analysis: Cardiovascular Risk With Sulfonylurea Plus Metformin Relative Risk (95% CI) Bruno (1999) Olsson (2000) Johnson (2005) Koro (2005) Evans (2006) (A) Evans (2006) (B) Evans (2006) (C) Overall 1.04 (0.62-1.75) 1.86 (1.33-2.61) 0.96 (0.82-1.12) 1.38 (1.13-1.69) 2.24 (1.26-3.99) 1.86 (1.03-3.35) 1.52 (0.84-2.76) 1.43 (1.10-1.85) 0.25 1.0 4.0 • Results With Combination Therapy • Increased composite cardiovascular risk end point (RR 1.43; 95% CI, 1.10-1.85) • All-cause mortality alone – not significant • Cardiovascular disease mortality alone – not significant Composite end point: cardiovascular hospitalization or mortality Relative risk: combination therapy vs. diet, metformin alone, or sulfonylurea alone Rao AD, et al. Diabetes Care. 2008;31:1672-1678. RR = relative risk

  13. Higher Mortality Is Associated With Greater Exposure to Sulfonylurea Monotherapy group Monotherapy group Deaths/1000 person-years Deaths/1000 person-years Hazard ratio Hazard ratio Adherence Daily Dose Poor (good) 1.55 1.34 1.33 49.0 (75.8) Glyburide (n = 4138) 1.10 1.09 0.98 Lower (higher) 1.32 1.29 1.29 37.7 (41.3) Metformin (n = 1537) 53.4 (70.2) Glyburide (n = 4138) 0 1 2 0.92 0.96 0.84 41.5 (37.6) Metformin (n = 1537) Unadjusted Adjusted for age, sex, chronic disease score (CDS), and nitrate use Adjusted for age, sex, CDS, nitrate use, physician visits, and hospital admissions 0 1 2 There was a greater risk of death associated with higher daily doses and better adherence for patients who used glyburide (HR = 1.3; 95% CI, 1.2-1.4), but not metformin (HR = 0.8; 95% CI, 0.7-1.1) • A retrospective, inception cohort study conducted in 5795 new users of oral glucose-lowering medications • - Insulin or combination therapy were excluded • - Mean age: 66.3 years • - Mean follow-up: 4.6 years • - Main outcomes: all-cause mortality, death from acute • ischemic event Simpson SH, et al. CMAJ. 2006;174:169-174.

  14. Decrease b-cell demand- - dec CV outcomes, STOP- NIDDM • Decrease HbA1c 0.5–1% • Decrease PPG,TG • Delay DM Adverse events: flatulence,treat hypoglycemia with glucose

  15. Other Meds with Glycemic Benefit Fast-acting Bromocryptine central dopaminergic effect on decreasing peripheral sympathetic tone decreasing insulin resistance Decreases CV outcomes 50% in 1 year Colsevelam lipid benefit (Ranolazine) Decrease angina ( or equivalent) Decreases arrhythmia Improves diastolic dysfunction, thus-decreases edema of Pio-, Decreases HgA1c, FBS in glucose dependent fashion , no hypoglycemia

More Related